Q2 2024 EPS Estimates for iTeos Therapeutics, Inc. Lifted by HC Wainwright (NASDAQ:ITOS)

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Stock analysts at HC Wainwright raised their Q2 2024 earnings estimates for shares of iTeos Therapeutics in a research note issued to investors on Monday, May 13th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($1.15) per share for the quarter, up from their prior forecast of ($1.34). HC Wainwright currently has a “Buy” rating and a $46.00 target price on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($4.72) per share. HC Wainwright also issued estimates for iTeos Therapeutics’ Q3 2024 earnings at ($1.21) EPS, Q4 2024 earnings at ($1.25) EPS, FY2024 earnings at ($4.70) EPS, Q3 2025 earnings at ($1.64) EPS, Q4 2025 earnings at ($1.78) EPS, FY2025 earnings at ($6.35) EPS, FY2026 earnings at ($3.63) EPS and FY2027 earnings at $0.16 EPS.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.18.

Separately, Wedbush reissued an “outperform” rating and set a $18.00 price target (down from $25.00) on shares of iTeos Therapeutics in a research report on Wednesday, March 6th.

iTeos Therapeutics Stock Down 0.3 %

Shares of ITOS opened at $17.90 on Thursday. The firm has a fifty day simple moving average of $12.27 and a two-hundred day simple moving average of $11.06. iTeos Therapeutics has a twelve month low of $8.20 and a twelve month high of $18.75. The stock has a market capitalization of $646.55 million, a P/E ratio of -4.74 and a beta of 1.27.

Institutional Trading of iTeos Therapeutics

Large investors have recently made changes to their positions in the stock. Kennedy Capital Management LLC purchased a new position in iTeos Therapeutics in the first quarter worth about $1,988,000. Public Employees Retirement System of Ohio grew its position in shares of iTeos Therapeutics by 4.9% during the first quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock worth $532,000 after purchasing an additional 1,817 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of iTeos Therapeutics in the first quarter worth $3,337,000. Vanguard Group Inc. boosted its position in shares of iTeos Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company’s stock worth $20,468,000 after acquiring an additional 9,660 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of iTeos Therapeutics by 66.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 6,877 shares of the company’s stock worth $94,000 after acquiring an additional 2,737 shares during the last quarter. 97.16% of the stock is currently owned by institutional investors.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.